{"nctId":"NCT00097500","briefTitle":"Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes","startDateStruct":{"date":"2004-09"},"conditions":["Type 2 Diabetes Mellitus"],"count":69,"armGroups":[{"label":"Exenatide Arm","type":"EXPERIMENTAL","interventionNames":["Drug: exenatide","Drug: Metformin"]},{"label":"Insulin Glargine Arm","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin glargine","Drug: Metformin"]}],"interventions":[{"name":"exenatide","otherNames":["Byetta"]},{"name":"Insulin glargine","otherNames":["Lantus"]},{"name":"Metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of type 2 diabetes, but otherwise healthy\n* HbA1c between 6.6% and 9.5%, inclusive.\n* Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive.\n* Treated with a stable dose of metformin for at least 2 months prior to screening.\n\nExclusion Criteria:\n\n* Patients previously in a study using exenatide.\n* Treated with oral anti-diabetic medications other than metformin within 2 months of screening (thiazolidinediones within 5 months of screening).\n* Treated with insulin within 3 months of screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Beta-cell Function After 52 Weeks of Therapy","description":"Treatment effect on beta-cell function as measured by the ratio of Week 52 arginine-stimulated insulin secretion during a hyperglycemic clamp(specifically, the incremental AUC of insulin with respect to basal value over a 10 min period \\[i.e., clamp time 290 min to 300 min\\]) to that at baseline (i.e., the ratio is calculated as arginine-stimulated insulin secretion at week 52 divided by arginine-stimulated insulin secretion at baseline \\[week -2\\]).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.89","spread":"0.27"},{"groupId":"OG001","value":"1.15","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Beta-cell Function 4 Weeks After Cessation of Therapy","description":"Treatment effect on beta-cell function as measured by the ratio of Week 56 arginine-stimulated insulin secretion during a hyperglycemic clamp(specifically, the incremental AUC of insulin with respect to basal value over a 10 min period \\[i.e., clamp time 290 min to 300 min\\]) to that at baseline (i.e., the ratio is calculated as arginine-stimulated insulin secretion at week 56 divided by arginine-stimulated insulin secretion at baseline \\[week -2\\]).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":"0.06"},{"groupId":"OG001","value":"1.08","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Change in First Phase C-peptide Release","description":"Ratio of first phase C-peptide response to glucose at 52 weeks (end of on-drug period) and 56 weeks (during off-drug period) compared to first phase C-peptide response to glucose at baseline (i.e., C-peptide response to glucose at week 52 or week 56 divided by C-peptide response to glucose at baseline \\[week -2\\]). C-peptide is measured as a surrogate marker of insulin secretion. First phase C-peptide/insulin release is measured during the first ten minutes of glucose infusion during a hyperglycemic clamp procedure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":"0.11"},{"groupId":"OG001","value":"1.13","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":"0.05"},{"groupId":"OG001","value":"1.06","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change in Second Phase C-peptide Release","description":"Ratio of second phase C-peptide response to glucose at 52 weeks (end of on-drug period) and 56 weeks (during off-drug period) compared to second phase C-peptide response to glucose at baseline (i.e., C-peptide response to glucose at week 52 or week 56 divided by C-peptide response to glucose at baseline \\[week -2\\]). C-peptide is measured as a surrogate marker of insulin secretion. Second phase C-peptide/insulin release is measured from time=10 minutes to time=80 minutes of glucose infusion during a hyperglycemic clamp procedure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.88","spread":"0.18"},{"groupId":"OG001","value":"1.01","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.05"},{"groupId":"OG001","value":"1.08","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change in Glycosylated Hemoglobin (HbA1c)","description":"Change in HbA1c from week 0 to week 52 (i.e., HbA1c at week 52 minus HbA1c at week 0).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":"0.14"},{"groupId":"OG001","value":"-0.87","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose","description":"Change in fasting plasma glucose from week 0 to week 52 (i.e., fasting plasma glucose at week 52 minus fasting plasma glucose at week 0).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.53","spread":"0.25"},{"groupId":"OG001","value":"-3.10","spread":"0.27"}]}]}]},{"type":"SECONDARY","title":"Seven Point Self Monitored Blood Glucose (SMBG) Measurements","description":"SMBG measured at 7 time points (before and after breakfast, before and after lunch, before and after dinner, at bedtime).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.92","spread":"1.80"},{"groupId":"OG001","value":"8.38","spread":"1.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.27","spread":"1.63"},{"groupId":"OG001","value":"5.63","spread":"0.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.00","spread":"2.58"},{"groupId":"OG001","value":"11.17","spread":"3.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.98","spread":"2.42"},{"groupId":"OG001","value":"7.53","spread":"2.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.14","spread":"2.25"},{"groupId":"OG001","value":"8.54","spread":"2.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.52","spread":"1.52"},{"groupId":"OG001","value":"6.24","spread":"1.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.90","spread":"2.54"},{"groupId":"OG001","value":"10.52","spread":"2.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.97","spread":"2.01"},{"groupId":"OG001","value":"8.15","spread":"1.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.38","spread":"2.40"},{"groupId":"OG001","value":"8.07","spread":"2.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.53","spread":"2.63"},{"groupId":"OG001","value":"6.98","spread":"2.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.42","spread":"2.42"},{"groupId":"OG001","value":"10.26","spread":"2.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.98","spread":"2.25"},{"groupId":"OG001","value":"8.81","spread":"2.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.76","spread":"2.44"},{"groupId":"OG001","value":"9.85","spread":"3.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.61","spread":"2.11"},{"groupId":"OG001","value":"8.03","spread":"2.82"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change in body weight from week 0 to week 52 (i.e., body weight at week 52 minus body weight at week 0).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.80","spread":"0.87"},{"groupId":"OG001","value":"0.75","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"M-value at Baseline, Week 52 and Week 56","description":"M-value at baseline (week -2), week 52 (end of on-drug period), and week 56 (during off-drug period). Insulin sensitivity was assessed during the euglycemic/hyperglycemic clamp test at baseline (week -2), week 52, and week 56. Insulin-mediated glucose uptake (M-value) was calculated as the mean glucose requirement during the 90-120 minute interval of the clamp.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.24","spread":"0.39"},{"groupId":"OG001","value":"2.79","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.18","spread":"0.42"},{"groupId":"OG001","value":"3.85","spread":"0.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.19","spread":"0.44"},{"groupId":"OG001","value":"2.81","spread":"0.29"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":36},"commonTop":["Nausea","Hypoglycemia","Influenza","Dyspepsia","Arthralgia"]}}}